Verus Acquires Anaphylaxis Treatment

Exclusive worldwide rights to a novel epinephrine auto-injector have been acquired by Verus Pharmaceuticals, Inc. (San Diego, CA, USA) from Hollister-Stier Laboratories LLC (Spokane, WA, USA). No financial details were discosed.

The epinephrine auto-injector, called Twinject, was approved by the U.S. Food and Drug Administration (FDA) in 2003. Two dosages are approved for self-administration: 0.3 mg and 0.15 mg. In addition to Twinject, Verus also acquired rights to other intellectual property and assets, including complementary and next-generation designs and ongoing development work.

"Twinject is the first and only product approved by the FDA that contains two doses of epinephrine in a single device,” said Robert W. Keith, president and COO of Verus. "This is an important feature of Twinject, as published studies have demonstrated that more than one dose of epinephrine may be required in many situations to properly address the allergic reaction, with the second dose often needed within five to 10 minutes after the first dose. As such, we are eager to bring this novel product line to market and are committed to working closely with patients, caregivers, and advocacy groups to develop additional products that address other unmet medical needs for those at risk.”

Hollister-Stier is a worldwide manufacturer of allergenic extracts targeted primarily at allergies and asthmas. Verus is building a portfolio of products for the unmet needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions.





Related Links:
Verus Pharma
Hollister-Stier